Post hoc AHA 2026 data show the oral GLP-1 receptor agonist lowered systolic blood pressure across hypertension stages, partly beyond weight loss.
|Articles|October 13, 2021
Daily Medication Pearl: Solriamfetol (Sunosi) for Excessive Daytime Sleepiness
Author(s)Saro Arakelians, PharmD
The mechanism of action of solriamfetol is mediated through its activity as a dopamine and norepinephrine reuptake inhibitor indicated for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.
Advertisement
Medication Pearl of the Day: Solriamfetol (Sunosi)
Indication: Solriamfetol is a dopamine and norepinephrine reuptake inhibitor (DNRI) indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).
Insight:
- Dosing: Starting dose for patients with narcolepsy is 75 mg once daily. Starting dose for patients with OSA is 37.5 mg once daily. Dose may be increased at intervals of at least 3 days. Maximum dose is 150 mg once daily.
- Dosage form: Tablets 75 mg (functionally scored) and 150 mg.
- Adverse events (AEs): Most common AEs are headache, nausea, decreased appetite, insomnia, and anxiety.
- Mechanism of action: The mechanism of action of solriamfetol is thought to be mediated through its activity as a dopamine and DNRI.
- Manufacturer: Jazz Pharmaceuticals
Sources:
Advertisement
Related to this article
Cody Parsons, APh, PharmD, BCCCP, says protected pharmacist access lets patients with heart failure be seen more often than typical clinic visits allow.
The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.
Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
Pharmacists can work alongside dermatologists, nurses, and other health care professionals to help answer skin care–related questions and help patients understand trial outcomes.
Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Understanding Kratom: Pharmacology, Safety, and Regulation
2
Orforglipron Lowers Systolic BP in ATTAIN-1, ATTAIN-2 Analyses
3
How Stanford Pharmacists Help Close Heart Failure Therapy Gaps
4
GLP-1s and Obesity Care: Cardiorenal Outcomes, Prescribing Considerations, and Access Barriers
5